These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25946762)

  • 1. The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine-resistant or intolerant FMF.
    Hashkes PJ; Huang B
    Isr Med Assoc J; 2015 Mar; 17(3):137-40. PubMed ID: 25946762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
    Hashkes PJ; Spalding SJ; Giannini EH; Huang B; Johnson A; Park G; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright DA; Kastner DL; Lovell DJ
    Ann Intern Med; 2012 Oct; 157(8):533-41. PubMed ID: 23070486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for reducing inflammation in familial Mediterranean fever.
    Yin X; Tian F; Wu B; Xu T
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2015 Mar; (3):CD010893. PubMed ID: 25791871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
    Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FMF50: a score for assessing outcome in familial Mediterranean fever.
    Ozen S; Demirkaya E; Duzova A; Erdogan O; Erken E; Gul A; Kasapcopur O; Kasifoglu T; Kisacik B; Ozdogan H; Tunca M; Acikel C;
    Ann Rheum Dis; 2014 May; 73(5):897-901. PubMed ID: 24570027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
    Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
    J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial.
    Ben-Zvi I; Livneh A
    Isr Med Assoc J; 2014 May; 16(5):271-3. PubMed ID: 24979828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
    Portincasa P; Scaccianoce G; Palasciano G
    Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments.
    Ozen S; Kone-Paut I; Gül A
    Semin Arthritis Rheum; 2017 Aug; 47(1):115-120. PubMed ID: 28413100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.
    Demirkaya E; Erer B; Ozen S; Ben-Chetrit E
    Rheumatol Int; 2016 Mar; 36(3):325-31. PubMed ID: 26687683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
    Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y; Gezer HH; Duruöz MT
    Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic approach to familial Mediterranean fever: a review update.
    Ozturk MA; Kanbay M; Kasapoglu B; Onat AM; Guz G; Furst DE; Ben-Chetrit E
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S77-86. PubMed ID: 21968242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colchicine treatment in children with familial Mediterranean fever.
    Ozkaya N; Yalçinkaya F
    Clin Rheumatol; 2003 Oct; 22(4-5):314-7. PubMed ID: 14579163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
    Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early predictors of colchicine resistance in familial Mediterranean fever.
    Mosad Mosa D; Shokry D; Ahmed DB; Sobh A
    Mod Rheumatol; 2023 Jul; 33(4):830-835. PubMed ID: 35789271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?
    Erden A; Batu ED; Sarı A; Sönmez HE; Armagan B; Demir S; Fırat E; Bilginer Y; Bilgen SA; Karadağ Ö; Kalyoncu U; Kiraz S; Ertenli I; Özen S; Akdogan A
    Clin Exp Rheumatol; 2018; 36(6 Suppl 115):97-102. PubMed ID: 30418112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.